retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Phase 2 Trial of Retatrutide

Retatrutide Manufacturing Requirements: Molecular weight: 4,731.20 Da Stability temperature: 2-8C storage pH stability range: 7.0-9.0 Purity specifications: 99.0% HPLC Peptide content: 80.0% Semaglutide Manufacturing Requirements: Molecular weight: 4,113.58 Da Stability temperature: 2-8C storage pH stability range: 7.4-8.2 Purity specifications: 95.0% HPLC Peptide content: 75.0% The broader pH stability range of retatrutide provides manufacturing advantages during formulation development and scale-up processes

With in-depth guidance about the management plan for weight loss, semaglutide promotes achieving your goals about weight loss and improving overall health and well-being

Retatrutide has a half-life of roughly 6 days, which means each weekly injection adds to the drug still circulating from previous doses

Dose escalation and what to expect at each level GLP-1 therapy always begins with a lower dose and escalates over weeks to months

Discuss with your healthcare provider

Retatrutide is a new weight loss drug from Eli Lilly and has promising results in clinical trials but is not yet available